Samir Parekh

List of Publications by Year
in descending order

108 papers	4,361 citations	257450 24 h-index	123424 61 g-index
111 all docs	111 docs citations	111 times ranked	9757 citing authors

#	Article	IF	Citations
1	An inflammatory cytokine signature predicts COVID-19 severity and survival. Nature Medicine, 2020, 26, 1636-1643.	30.7	1,860
2	Oral Selinexorâ€“Dexamethasone for Triple-Class Refractory Multiple Myeloma. New England Journal of Medicine, 2019, 381, 727-738.	27.0	460
3	Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. Cancer Cell, 2021, 39, 1028-1030.	16.8	176
4	Discovery of a first-in-class EZH2 selective degrader. Nature Chemical Biology, 2020, 16, 214-222.	8.0	148
5	Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. Blood, 2010, 116, 1025-1034.	1.4	138
6	BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. Blood, 2007, 110, 2067-2074.	1.4	117
7	Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia. Cell Stem Cell, 2017, 20, 315-328.e7.	11.1	114
8	A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. Journal of Hematology and Oncology, 2020, 13, 94.	17.0	107
9	Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nature Medicine, 2021, 27, 2099-2103.	30.7	92
10	A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy. Cancer Discovery, 2021, 11, 599-613.	9.4	90
11	Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma. Clinical Cancer Research, 2020, 26, 450-464.	7.0	62
12	Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma. Cancer Cell, 2021, 39, 1442-1444.	16.8	62
13	Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications. Science Advances, 2021, 7, eabg9551.	10.3	49
14	Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies. Frontiers in Immunology, 2018, 9, 2616.	4.8	44
15	Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia. Science Translational Medicine, 2015, 7, 293ra102.	12.4	43
16	Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma. Haematologica, 2022, 107, 690-701.	3.5	43
17	Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas. Leukemia and Lymphoma, 2008, 49, 874-882.	1.3	41
18	Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R in MYC-Rearranged Aggressive B-Cell Lymphoma. Blood, 2014, 124, 395-395.	1.4	40

#	Article	IF	Citations
19	A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma. Blood Advances, 2017, 1, 1575-1583.	5.2	39
20	Dynamic CD138 surface expression regulates switch between myeloma growth and dissemination. Leukemia, 2020, 34, 245-256.	7.2	38
21	SOX11 augments BCR signaling to drive MCL-like tumor development. Blood, 2018, 131, 2247-2255.	1.4	37
22	New molecular targets in mantle cell lymphoma. Seminars in Cancer Biology, 2011, 21, 335-346.	9.6	35
23	Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling. Blood Advances, 2018, 2, 1470-1479.	5.2	31
24	Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 632-636.e1.	0.4	31
25	Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients. Cancer Cell, 2022, 40, 441-443.	16.8	29
26	Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma. Cancer Research, 2016, 76, 1225-1236.	0.9	25
27	Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research, 2020, 26, 5895-5902.	7.0	25
28	A Network Analysis of Multiple Myeloma Related Gene Signatures. Cancers, 2019, 11, 1452.	3.7	23
29	Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics Approach. JCO Precision Oncology, 2018, 2018, 1-17.	3.0	20
30	Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based review. Expert Review of Hematology, 2020, 13, 943-958.	2.2	16
31	Adverse drug reaction: pomalidomide-induced liver injury. Lancet, The, 2014, 383, 2125-2126.	13.7	15
32	Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma. Oncotarget, 2015, 6, 27332-27342.	1.8	15
33	Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R. Blood, 2015, 126, 342-342.	1.4	14
34	A Phase II Study of Panobinostat with Lenalidomide and Weekly Dexamethasone in Myeloma. Blood, 2015, 126, 4226-4226.	1.4	14
35	Integrative network modeling approaches to personalized cancer medicine. Personalized Medicine, 2015, 12, 245-257.	1.5	12
36	Efficacy of Intravenous Immunoglobulin for Preventing Infections in Patients with Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e470-e476.	0.4	12

#	Article	IF	Citations
37	MAGE-A inhibit apoptosis and promote proliferation in multiple myeloma through regulation of BIM and p21Cip1. Oncotarget, 2020, 11, 727-739.	1.8	12
38	A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma. Blood, 2011, 118, 779-779.	1.4	11
39	Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma. Therapeutic Advances in Hematology, 2021, 12, 204062072098707.	2.5	10
40	The effect of novel therapies in high-molecular-risk multiple myeloma. Clinical Advances in Hematology and Oncology, 2017, 15, 870-879.	0.3	10
41	Minimal Residual Disease in Multiple Myeloma: Impact on Response Assessment, Prognosis and Tumor Heterogeneity. Advances in Experimental Medicine and Biology, 2018, 1100, 141-159.	1.6	9
42	Where you live can impact your cancer risk: a look at multiple myeloma in New York City. Annals of Epidemiology, 2020, 48, 43-50.e4.	1.9	9
43	Phase 1b trial of isatuximab, an antiâ€CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma. Cancer, 2021, 127, 1816-1826.	4.1	9
44	Weighted Gene Co-Expression Network Analysis (WGCNA) Identifies Highly Proliferative Myeloma Subgroup Responsive to CDK4/ARK5 Inhibition. Blood, 2014, 124, 3445-3445.	1.4	9
45	Epigenetic Determinants of Pathogenesis and Resistance to Proteosome Inhibition in Mantle Cell Lymphoma.. Blood, 2008, 112, 3373-3373.	1.4	8
46	Outcomes and Management of Red Blood Cell Transfusions in Multiple Myeloma Patients Treated with Daratumumab. Blood, 2015, 126, 3571-3571.	1.4	8
47	Effect of Intravenous Immunoglobulin on Infections in Multiple Myeloma (MM) Patients Receiving Daratumumab. Blood, 2020, 136, 6-7.	1.4	8
48	A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma. Leukemia and Lymphoma, 2020, 61, 2208-2215.	1.3	7
49	A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma. Expert Review of Hematology, 2021, 14, 31-45.	2.2	7
50	Final Results of a Phase 1-2 Study of Vorinostat (SAHA), Cladribine, and Rituximab (SCR) Relapsed B-Cell Non-Hodgkinâ€™s Lymphoma and Previously Untreated Mantle Cell Lymphoma. Blood, 2014, 124, 1714-1714.	1.4	7
51	A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma. JCO Precision Oncology, 2022, , .	3.0	7
52	SOX11 Inhibitors Are Cytotoxic in Mantle Cell Lymphoma. Clinical Cancer Research, 2021, 27, 4652-4663.	7.0	6
53	CD25 (IL2RA) Orchestrates Negative Feedback Control and Stabilizes Oncogenic Signaling Strength in Acute Lymphoblastic Leukemia. Blood, 2015, 126, 1434-1434.	1.4	6
54	Clinical Outcomes and Treatment Strategies for Relapsed/Refractory Myeloma Patients after Relapse on BCMA-Targeted CAR T. Blood, 2021, 138, 2704-2704.	1.4	6

#	Article	IF	Citations
55	Human immunodeficiency virus-associated lymphoma. Clinical Advances in Hematology and Oncology, 2003, 1, 295-301.	0.3	6
56	Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biology of Blood and Marrow Transplantation, 2020, 26, e247-e255.	2.0	5
57	Optimal Supportive Care With Selinexor Improves Outcomes in Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e975-e984.	0.4	5
58	Single-Cell Profiling Reveals Contribution of Tumor Extrinsic and Intrinsic Factors to BCMA-Targeted CAR-T Cell Efficacy in Multiple Myeloma. Blood, 2021, 138, 326-326.	1.4	5
59	Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies. Open Forum Infectious Diseases, 2022, 9, .	0.9	5
60	A Phase I/II Study of Vorinostat (SAHA), Cladribine (2-CdA), and Rituximab Shows Significant Activity in Previously Untreated Mantle Cell Lymphoma. Blood, 2011, 118, 441-441.	1.4	4
61	Large-Scale Mass Cytometry Reveals Significant Activation of Innate and Adaptive Immunity in Bone Marrow Tumor Microenvironment of Iberdomide-Treated Myeloma Patients. Blood, 2021, 138, 730-730.	1.4	4
62	Targeting HSF1: A Prime Integrator of Proteotoxic Stress Response in Myeloma. Clinical Cancer Research, 2018, 24, 2237-2238.	7.0	3
63	Genomic and Pathway Connectivity Analyses Identify Novel Strategies to Overcome mTOR Inhibitor Resistance In DLBCL. Blood, 2010, 116, 436-436.	1.4	3
64	Combined Epigenetic and Immunotherapy For Newly Diagnosed Mantle Cell Lymphoma: Correlative Studies Suggest The Importance Of Enhanced ADCC, Mechanisms of Resistance and Cyclin D1 Nuclear Localization Genotype. Blood, 2013, 122, 3063-3063.	1.4	3
65	A Phase II, Single-Center, Open-Label Study of Oral Panobinostat in Combination with Lenalidomide and Weekly Dexamethasone in Patients with Multiple Myeloma. Blood, 2014, 124, 3486-3486.	1.4	3
66	MAGE-a Mediate Resistance to Chemotherapy in Multiple Myeloma through Regulation of Bcl-2 Proteins. Blood, 2016, 128, 3277-3277.	1.4	3
67	A Phase II Study of Pomalidomide, Daily Low Dose Oral Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma. Blood, 2016, 128, 4520-4520.	1.4	3
68	Synergistic Combinations of Histone Deacetylase Inhibitors and Decitabine Induce a Unique Gene Expression and Epigenetic Profile In Models of Diffuse Large B-Cell Lymphoma. Blood, 2010, 116, 435-435.	1.4	3
69	The Safety and Efficacy of Radiation Therapy with Concurrent Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin-Based Systemic Therapy for Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.4	3
70	Taking it up a notch in MCL. Blood, 2012, 119, 1957-1958.	1.4	2
71	Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma. Annals of Hematology, 2020, 100, 3057-3060.	1.8	2
72	Timing of Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Current Therapies. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e734-e751.	0.4	2

#	Article	IF	Citations
73	Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD). Leukemia and Lymphoma, 2021, 62, 2981-2991.	1.3	2
74	Recapturing Disease Response: A Phase II Study of High Dose Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma Who Have Progressed on Standard Dose Carfilzomib. Blood, 2015, 126, 3051-3051.	1.4	2
75	Flow Cytometry Based Detection of MRD in Bone Marrow of Patients with Multiple Myeloma: A Comparison Between Fluorescent-Based Cytometry Versus Cytof. Blood, 2015, 126, 4195-4195.	1.4	2
76	Inhibiting SOX11-DNA Interaction in Mantle Cell Lymphoma. Blood, 2016, 128, 1840-1840.	1.4	2
77	CD25 Enables Oncogenic BCR Signaling and Represents a Therapeutic Target in Refractory B Cell Malignancies. Blood, 2016, 128, 4088-4088.	1.4	2
78	SOX11 Directly Represses Wnt/Î²-Catenin Signaling and Identifies a Subgroup of Mantle Cell Lymphoma Patients with Improved Survival with Intensive Treatment. Blood, 2012, 120, 895-895.	1.4	2
79	A Machine Learning Approach Identifies a 30-Gene Model That Predicts Sensitivity to Selinexor in Multiple Myeloma. Blood, 2019, 134, 3101-3101.	1.4	2
80	(Distinct) origins of IgM myeloma. Blood, 2021, 138, 1914-1915.	1.4	2
81	Treatment Bridging With a 28-Day Metronomic Therapy (Metro-28) for Relapsed Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 129-132.	0.4	1
82	Outcomes in Multiple Myeloma Patients Progressing on Lenalidomide Maintenance. Blood, 2019, 134, 1779-1779.	1.4	1
83	BCL6 Programs Lymphoma Cells for Survival and Differentiation through Distinct Biochemical Mechanisms, Both of Which Can Be Therapeutically Targeted.. Blood, 2006, 108, 225-225.	1.4	1
84	High-Resolution Sequencing Identifies NOXA1 De-Methylation As a Novel Strategy to Overcome Bortezomib Resistance in Mantle Cell Lymphoma. Blood, 2011, 118, 557-557.	1.4	1
85	Vorinostat (SAHA), Cladribine, and Rituximab in Previously Untreated Mantle Cell Lymphoma: Updated Results From a Phase I/II Trial. Blood, 2012, 120, 3675-3675.	1.4	1
86	IL2RA (CD25) Recruits Inhibitory Phosphatases to the Cell Membrane and Mediates Negative Feedback Control of STAT5 Signaling in Acute Lymphoblastic Leukemia. Blood, 2014, 124, 788-788.	1.4	1
87	SOX11 Cooperates with CCND1 in Mantle Cell Lymphoma Pathogenesis. Blood, 2015, 126, 1253-1253.	1.4	1
88	Phase 1 Study of Elotuzumab in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma. Blood, 2016, 128, 3448-3448.	1.4	1
89	Network Modeling Reveals CDC42BPA and CLEC11A As Novel Driver Genes of t(4; 14) Multiple Myeloma. Blood, 2016, 128, 802-802.	1.4	1
90	Integrative Network Analysis of Newly Diagnosed Multiple Myeloma Identifies a Novel RNA-Seq Based High Riskgene Signature. Blood, 2016, 128, 3285-3285.	1.4	1

#	Article	IF	Citations
91	Aberrant Cell Cycle Programming Confers Rapid Lethality in the EuSOX11+ CCND1 MCL Mouse Model. Blood, 2020, 136, 6-7.	1.4	1
92	Recapturing disease response: A phase 2 study of carfilzomib 56â€‰mg/m² in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27â€‰mg/m². American Journal of Hematology, 2020, 95, E51-E54.	4.1	0
93	Continuous genomic monitoring of multiple myeloma patients to identify patients of high risk for poor prognosis.. Journal of Clinical Oncology, 2021, 39, e20035-e20035.	1.6	0
94	Genome-Wide Methylation Analysis of Primary Mantle Cell Lymphomas Identifies Novel Gene Targets for Epigenetic Drug Therapy.. Blood, 2009, 114, 673-673.	1.4	0
95	High-Resolution Chromatin Immunoprecipitation (ChIP) Sequencing Identifies Novel Binding Targets and Prognostic Role for SOX11 in Mantle Cell Lymphoma. Blood, 2011, 118, 585-585.	1.4	0
96	Parallel Transcriptional Analysis of Multiple Stem and Progenitor Populations Identifies Novel Commonly Dysregulated and Functionally Relevant Targets in AML. Blood, 2012, 120, 1875-1875.	1.4	0
97	High-Resolution Genomic Methylation Analysis Using Next Generation Sequencing Identifies Loci Associated With Differential Prognosis In Mantle Cell Lymphoma Patients Treated With Bortezomib + DA-EPOCH-R. Blood, 2013, 122, 3760-3760.	1.4	0
98	Patient-Specific Mutation-Derived Tumor Antigens As Targets for Cancer Immunotherapy in Multiple Myeloma. Blood, 2015, 126, 1851-1851.	1.4	0
99	Towards a Network-Based Molecular Taxonomy of Newly Diagnosed Multiple Myeloma. Blood, 2015, 126, 840-840.	1.4	0
100	Aberrant a-to-I RNA Editing and Prognostic Impact of Adar in Multiple Myeloma Patients with 1q Amplification. Blood, 2016, 128, 357-357.	1.4	0
101	Mutation Burden in Multiple Myeloma Is Captured By Gene Expression Profiles. Blood, 2016, 128, 4450-4450.	1.4	0
102	Genomic and Immunologic Analysis of Cmaf and Hypermutated Multiple Myeloma: Implications for Immunologic Therapy. Blood, 2019, 134, 3093-3093.	1.4	0
103	High Dimensional Immune Profiling in Smoldering Multiple Myeloma Identifies Novel Organizing Features of the Tumor Microenvironment. Blood, 2019, 134, 4384-4384.	1.4	0
104	Title: Genomic and Systemic Metabolism Differences Associated with Racial Disparities in Multiple Myeloma. Blood, 2021, 138, 1601-1601.	1.4	0
105	Triple MAPK Inhibition Salvaged a Relapsed Post BCMA CAR-T Cell Therapy in Multiple Myeloma Patient with BRAF V600E Dominant Clone. Blood, 2021, 138, 4720-4720.	1.4	0
106	28-Day Metronomic Therapy for Relapsed Refractory Multiple Myeloma. Blood, 2020, 136, 13-13.	1.4	0
107	289â€…PGV-001: a phase 1 trial of a personalized neoantigen peptide vaccine for the treatment of malignancies in the adjuvant setting. , 2020, , .		0
108	CD8+ TÂcells: An ineffective armor against prolonged COVID-19 in cancer patients. Cell Reports Medicine, 2022, , 100695.	6.5	0